VIPoma risk factors: Difference between revisions
Jump to navigation
Jump to search
Homa Najafi (talk | contribs) No edit summary |
Homa Najafi (talk | contribs) |
||
| Line 5: | Line 5: | ||
The most common risk factor in the development of VIPoma is a positive family history of [[multiple endocrine neoplasia type 1]]. | The most common risk factor in the development of VIPoma is a positive family history of [[multiple endocrine neoplasia type 1]]. | ||
==Risk Factors== | ==Risk Factors== | ||
* The most common risk factor in the development of VIPoma is a positive family history of [[multiple endocrine neoplasia type 1]]. | * The most common risk factor in the development of VIPoma is a positive family history of [[multiple endocrine neoplasia type 1]].<ref name="PerryVinik1995">{{cite journal|last1=Perry|first1=R R|last2=Vinik|first2=A I|title=Clinical review 72: diagnosis and management of functioning islet cell tumors.|journal=The Journal of Clinical Endocrinology & Metabolism|volume=80|issue=8|year=1995|pages=2273–2278|issn=0021-972X|doi=10.1210/jcem.80.8.7629220}}</ref> | ||
* | * The most cases of VIPoma are sporadic whereas in 5% of cases are associated with MEN-1. | ||
==References== | ==References== | ||
Revision as of 15:27, 4 October 2019
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma risk factors On the Web |
|
American Roentgen Ray Society Images of VIPoma risk factors |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2]Parminder Dhingra, M.D. [3] Homa Najafi, M.D.[4]
Overview
The most common risk factor in the development of VIPoma is a positive family history of multiple endocrine neoplasia type 1.
Risk Factors
- The most common risk factor in the development of VIPoma is a positive family history of multiple endocrine neoplasia type 1.[1]
- The most cases of VIPoma are sporadic whereas in 5% of cases are associated with MEN-1.
References
- ↑ Perry, R R; Vinik, A I (1995). "Clinical review 72: diagnosis and management of functioning islet cell tumors". The Journal of Clinical Endocrinology & Metabolism. 80 (8): 2273–2278. doi:10.1210/jcem.80.8.7629220. ISSN 0021-972X.